GoodRx (GDRX) Stock Price, News & Analysis

Company Overview

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Key Stats

• Today's Range: $7.06 to $7.44
• 50-Day Range: $6.78 to $9.05
• 52-Week Range: $4.14 to $9.26
• Volume: 1.20 million shs
• Average Volume: 1.45 million shs
• Market Capitalization: $2.66 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.36
• Consensus Rating: Moderate Buy

GoodRx Stock Analysis - MarketRank™

GoodRx scored higher than 60% of companies evaluated by MarketBeat, and ranked 522nd out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

GoodRx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 53.33%

Earnings Growth

Earnings for GoodRx are expected to grow by 53.33% in the coming year, from $0.15 to $0.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GoodRx is -707.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GoodRx is -707.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

GoodRx has a PEG Ratio of 3.55. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GoodRx has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.11% of the float of GoodRx has been sold short.

Short Interest Ratio / Days to Cover

GoodRx has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in GoodRx has recently increased by 9.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GoodRx does not currently pay a dividend.

Dividend Growth

GoodRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.11% of the float of GoodRx has been sold short.

Short Interest Ratio / Days to Cover

GoodRx has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in GoodRx has recently increased by 9.99%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.30

News Sentiment

GoodRx has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for GoodRx this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.

MarketBeat Follows

5 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,921.00 in company stock.

Percentage Held by Insiders

Only 4.17% of the stock of GoodRx is held by insiders.

Percentage Held by Institutions

63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GDRX Stock Analysis - Frequently Asked Questions

How have GDRX shares performed this year?

GoodRx's stock was trading at $6.70 at the start of the year. Since then, GDRX stock has increased by 5.7% and is now trading at $7.08.
View the best growth stocks for 2024 here.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings data on Thursday, August, 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by $0.01. The firm's revenue for the quarter was up 5.7% compared to the same quarter last year.

When did GoodRx IPO?

GoodRx (GDRX) raised $900 million in an initial public offering on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Who are GoodRx's major shareholders?

GoodRx's top institutional shareholders include Millennium Management LLC (1.10%), Rubric Capital Management LP (1.00%), Renaissance Technologies LLC (0.79%) and American Century Companies Inc. (0.62%). Insiders that own company stock include Scott Wagner, Equity Vii LP Spectrum, Idea Men, Llc, Abdiel Capital Management, Llc, Trevor Bezdek, Babak Azad, Karsten Voermann, Bansi Nagji, Andrew Slutsky and Douglas Joseph Hirsch.
View institutional ownership trends.

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH) and Rocket Companies (RKT).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Data processing & preparation
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:GDRX
• CUSIP: N/A
• CIK: 1809519
• Web: www.goodrx.com
• Phone: 855-268-2822
• Fax: N/A
• Employees: 950
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.36
• High Stock Price Target: $16.00
• Low Stock Price Target: $4.50
• Potential Upside/Downside: +32.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 47.20
• P/E Growth: 3.55
• Net Income: $-8,870,000.00
• Net Margins: -7.57%
• Pretax Margin: -7.65%
• Return on Equity: 3.63%
• Return on Assets: 1.72%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 7.32
• Quick Ratio: 7.32

Sales & Book Value

• Annual Sales: $775.09 million
• Price / Sales: 3.43
• Cash Flow: $0.39 per share
• Price / Cash Flow: 18.14
• Book Value: $1.93 per share
• Price / Book: 3.67

Miscellaneous

• Outstanding Shares: 375,205,000
• Free Float: 359,559,000
• Market Cap: $2.66 billion
• Optionable: Optionable
• Beta: 1.38